EBS - Emergent BioSolutions Inc.

NYSE - NYSE Delayed Price. Currency in USD
62.34
-0.26 (-0.42%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close62.60
Open63.14
Bid0.00 x 900
Ask0.00 x 800
Day's Range61.50 - 63.45
52 Week Range42.67 - 73.89
Volume517,301
Avg. Volume418,826
Market Cap3.176B
Beta (3Y Monthly)1.75
PE Ratio (TTM)31.82
EPS (TTM)1.96
Earnings DateFeb 20, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.63
Trade prices are not sourced from all markets
  • Markit4 days ago

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    # Emergent Biosolutions Inc ### NYSE:EBS View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for EBS with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.61 billion over the last one-month into ETFs that hold EBS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journals9 days ago

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
    Zacks10 days ago

    Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

    Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

  • Emergent BioSolutions CEO to step down
    American City Business Journals12 days ago

    Emergent BioSolutions CEO to step down

    Daniel Abdun-Nabi will retire as CEO of Emergent BioSolutions Inc. (NYSE: EBS) after leading the Gaithersburg biotech through a pivotal seven-year period. Bob Kramer, the company’s current president and chief operating officer, will succeed Abdun-Nabi as president and CEO, effective April 1. Beginning April 1, he’ll serve as a consultant to the company, to provide guidance on strategic plan development, mergers and acquisitions, other transactions and regulatory matters, and to help with the executive transition, according to Securities and Exchange Commission filings.

  • Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
    Zacks12 days ago

    Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed

    Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.

  • GlobeNewswire12 days ago

    Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast

    Full year 2018 preliminary performance in line with recently revised guidanceFull year 2019 forecast reflects continued growth of organic business and anticipated positive.

  • Our Take On Emergent BioSolutions Inc.’s (NYSE:EBS) CEO Salary
    Simply Wall St.15 days ago

    Our Take On Emergent BioSolutions Inc.’s (NYSE:EBS) CEO Salary

    In 2012 Dan Abdun-Nabi was appointed CEO of Emergent BioSolutions Inc. (NYSE:EBS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • GlobeNewswire15 days ago

    Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO

    Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.

  • Emergent (EBS) Files Application for Emergency Use of NuThrax
    Zacks19 days ago

    Emergent (EBS) Files Application for Emergency Use of NuThrax

    Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

  • GlobeNewswire22 days ago

    Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™

    NuThrax, also known as AV7909, is being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. This submission is anticipated to undergo review by FDA through the first half of 2019.

  • Hedge Funds Are Buying Emergent Biosolutions Inc (EBS)
    Insider Monkeylast month

    Hedge Funds Are Buying Emergent Biosolutions Inc (EBS)

    Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]

  • Reuterslast month

    U.S. FDA panel backs prescribing opioid overdose reversal drug along with painkillers

    An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended prescribing the opioid overdose reversal drug, naloxone, along with addictive painkillers. The prescription of naloxone could facilitate a healthy dialogue between patients and the healthcare provider, Maryann Amirshahi, a panel member who voted in favor, said. Naloxone, when administered quickly, helps reverse the effects of opioid overdose and thereby save lives.

  • GlobeNewswirelast month

    Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)

    Emergent BioSolutions Inc. (EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in individuals 18 through 65 years of age, whose occupation or other activities place them at risk of exposure, regardless of the route of exposure. BioThrax was approved under the Extraordinary Use New Drug Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible.

  • See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Read This Before Judging Emergent BioSolutions Inc’s (NYSE:EBS) ROE
    Simply Wall St.last month

    Read This Before Judging Emergent BioSolutions Inc’s (NYSE:EBS) ROE

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?

    Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
    Zacks2 months ago

    Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint

    Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.

  • Reuters2 months ago

    Emergent-Valneva Zika vaccine clears early trial

    A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday. The vaccine, VLA1601, which was tested in two doses in 67 adult patients, induced the body to produce neutralizing antibodies against the virus, the companies said. First discovered in 1947, the Zika virus reached epidemic proportions in Brazil in 2015, when thousands of babies were born with birth defects.

  • GlobeNewswire2 months ago

    Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus

    GAITHERSBURG, Md. and SAINT-HERBLAIN, France, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The highly purified inactivated vaccine candidate, VLA1601, met the study’s primary endpoint showing a favorable safety profile in all doses and schedules tested. VLA1601 was also immunogenic in all treatment groups and induced both dose- and schedule-dependent neutralizing antibodies against the Zika virus with the kinetics expected for an inactivated, alum-adjuvanted whole-virus vaccine.

  • GlobeNewswire2 months ago

    EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS

    GAITHERSBURG, Md. and Saint-Herblain, France, November 19, 2018 - Emergent BioSolutions Inc. (EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The highly purified inactivated vaccine candidate, VLA1601, met the study`s primary endpoint showing a favorable safety profile in all doses and schedules tested. VLA1601 was also immunogenic in all treatment groups and induced both dose- and schedule-dependent neutralizing antibodies against the Zika virus with the kinetics expected for an inactivated, alum-adjuvanted whole-virus vaccine.

  • See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

    Emergent Biosolutions Inc NYSE:EBS

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of EBS earnings conference call or presentation 1-Nov-18 9:00pm GMT

    Q3 2018 Emergent BioSolutions Inc Earnings Call